EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization

Nayana Patel, Padma Rekha Jirge, Shalini Srivastava, Neena Malhotra, Sanjeeva Reddy, Vyjayanthi Srinivasan, Mirudhubashini Govindarajan, Manish Banker, Enrica Gravotta, Ali Falahati, Rita Lobo

Frontiers in Reproductive Health · 17.11.2026 · 8

DOI: 10.3389/frph.2026.1916232 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Reproductive Health, online erschienen am 17.11.2026. Verfasst von Nayana Patel und 10 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Women of Indian ethnicity are underrepresented among randomized controlled trials (RCTs) in reproductive medicine. We compared individualized follitropin delta with conventional follitropin alfa in infertile Indian women undergoing their first ovarian stimulation cycle for (IVF) or intracytoplasmic sperm injection (ICSI).

Methods

Indian participants, 21–40 years, were recruited from specialist fertility clinics across India to enroll in this assessor-blinded, multicenter bridging trial. Participants were randomly assigned (1:1) to individualized follitropin delta (algorithmic dosing based on serum anti-Müllerian hormone and bodyweight) or conventional follitropin alfa (starting dose 150 IU/day) in a GnRH antagonist protocol. The primary endpoint was the ongoing pregnancy rate per initiated cycle, and treatment difference was adjusted for age stratum (<35, 35–37 and 38–40 years) using the Mantel-Haenszel method. Secondary endpoints included ovarian responses, safety, and tolerability. An exploratory post hoc multivariate logistic analysis for ongoing pregnancy was performed using treatment group, age, AMH subgroup (<15 or ≥15 pmol) and infertility history as covariates.

Findings

Between 03-Dec-2021, and 13-Dec-2023, 249 participants were screened, 215 randomized, and 213 exposed to the study drug [ n = 99 follitropin delta; n = 114 follitropin alfa; modified intention-to-treat (mITT) analysis set]. Baseline characteristics were mostly similar between groups. The ongoing pregnancy rate was 22.2% (22/99) with follitropin delta vs. 14.9% (17/114) with follitropin alfa (age-adjusted difference 6.9% [95% CI −3.4–17.3]; post hoc multivariate adjusted difference 10.1%; odds ratio 1.99 [95% CI 0.95, 4.19]; p = 0.692). Participants had a mean oocyte yield ± standard deviation of 7.7 ± 5.3 in the follitropin delta group and 6.9 ± 4.2 in the follitropin alfa group. The mean total gonadotropin dose was ∼26% lower with follitropin delta (mean treatment difference −32.0 µg; p < 0.001, post-hoc analysis; mITT). The incidence of adverse events was similar between groups (34.3% vs. 29.8%), with no cases of OHSS reported.

Interpretation

The IRIS trial demonstrates that individualized dosing of follitropin delta is an effective and safe strategy for ovarian stimulation in Indian women while reducing total gonadotropin dose requirements. Ongoing pregnancy rates were numerically higher with follitropin delta in both the primary analysis and the post hoc multivariate logistic regression analysis, confirming the robustness of the results. Funding Ferring Pharmaceuticals A/S Registration ClinicalTrials.gov: NCT04773353; CTRI: CTRI/2021/04/032835.

Zitieren

APA

Patel, N., Jirge, P. R., Srivastava, S., Malhotra, N., Reddy, S., Srinivasan, V., Govindarajan, M., Banker, M., Gravotta, E., Falahati, A., & Lobo, R. (2026). IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization. Frontiers in Reproductive Health, 8. https://doi.org/10.3389/frph.2026.1916232

Vancouver

Patel N, Jirge PR, Srivastava S, Malhotra N, Reddy S, Srinivasan V, et al. IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization. Frontiers in Reproductive Health. 2026;8. doi:10.3389/frph.2026.1916232

BibTeX
@article{Patel2026,
  author = {Patel, Nayana and Jirge, Padma Rekha and Srivastava, Shalini and Malhotra, Neena and Reddy, Sanjeeva and Srinivasan, Vyjayanthi and Govindarajan, Mirudhubashini and Banker, Manish and Gravotta, Enrica and Falahati, Ali and Lobo, Rita},
  title = {IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization},
  journal = {Frontiers in Reproductive Health},
  year = {2026},
  volume = {8},
  doi = {10.3389/frph.2026.1916232}
}
Kostenlos starten →